Research programme: pulmonary fibrosis theraputics - Roche

Drug Profile

Research programme: pulmonary fibrosis theraputics - Roche

Alternative Names: ITMN-10534; ITMN-14440; ITMN-30162

Latest Information Update: 29 Oct 2014

Price : $50

At a glance

  • Originator InterMune
  • Developer Roche
  • Class Small molecules
  • Mechanism of Action Collagen inhibitors; Cytokine inhibitors; Lysophosphatidic acid receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Pulmonary fibrosis

Most Recent Events

  • 10 Jan 2014 Preclinical trials in Pulmonary fibrosis in USA (unspecified route)
  • 29 Feb 2012 Early research in Pulmonary fibrosis in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top